Rfg Advisory, LLC Amgen Inc Transaction History

Rfg Advisory, LLC

$3.18 Billion
Q3 2024

A detailed history of Rfg Advisory, LLC transactions in Amgen Inc stock. As of the latest transaction made, Rfg Advisory, LLC holds 10,830 shares of AMGN stock, worth $2.86 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

10,830

Previous 11,053 2.02%

Holding current value

$2.86 Million

Previous $3.45 Million 1.04%

% of portfolio

0.11%

Previous 0.12%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	SELL	$309.38 - $337.38 $68,991 - $75,235	-223 Reduced 2.02%	10,830 $3.49 Million
Q2 2024 Jul 15, 2024	BUY	$262.75 - $319.31 $74,095 - $90,045	282 Added 2.62%	11,053 $3.45 Million
Q1 2024 Apr 11, 2024	SELL	$268.87 - $324.56 $112,118 - $135,341	-417 Reduced 3.73%	10,771 $3.06 Million
Q4 2023 Jan 25, 2024	SELL	$255.7 - $288.46 $137,310 - $154,903	-537 Reduced 4.58%	11,188 $3.22 Million
Q3 2023 Oct 16, 2023	BUY	$218.65 - $271.46 $89,209 - $110,755	408 Added 3.61%	11,725 $3.15 Million
Q2 2023 Aug 03, 2023	BUY	$214.27 - $253.37 $102,421 - $121,110	478 Added 4.41%	11,317 $2.51 Million
Q1 2023 May 09, 2023	SELL	$225.79 - $275.2 $85,800 - $104,576	-380 Reduced 3.39%	10,839 $2.62 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $7,787 - $9,894	34 Added 0.3%	11,219 $2.95 Million
Q3 2022 Nov 10, 2022	BUY	$224.46 - $253.15 $71,378 - $80,501	318 Added 2.93%	11,185 $3.27 Million
Q2 2022 Aug 09, 2022	BUY	$230.71 - $256.74 $24,224 - $26,957	105 Added 0.98%	10,867 $2.68 Million
Q1 2022 May 11, 2022	BUY	$219.27 - $242.57 $353,463 - $391,022	1,612 Added 17.62%	10,762 $2.6 Million
Q4 2021 Feb 02, 2022	BUY	$198.88 - $227.6 $65,829 - $75,335	331 Added 3.75%	9,150 $2.06 Million
Q3 2021 Oct 19, 2021	BUY	$212.27 - $248.7 $106,347 - $124,598	501 Added 6.02%	8,819 $1.88 Million
Q2 2021 Jul 29, 2021	BUY	$233.58 - $259.14 $5,839 - $6,478	25 Added 0.3%	8,318 $2.03 Million
Q1 2021 Apr 19, 2021	SELL	$221.91 - $258.6 $4,660 - $5,430	-21 Reduced 0.25%	8,293 $2.06 Million
Q4 2020 Feb 02, 2021	SELL	$216.38 - $257.67 $333,225 - $396,811	-1,540 Reduced 15.63%	8,314 $1.98 Million
Q3 2020 Oct 13, 2020	SELL	$234.65 - $260.95 $233,007 - $259,123	-993 Reduced 9.15%	9,854 $2.5 Million
Q2 2020 Aug 03, 2020	BUY	$197.81 - $242.74 $118,488 - $145,401	599 Added 5.85%	10,847 $2.56 Million
Q1 2020 Apr 17, 2020	BUY	$182.24 - $241.7 $96,222 - $127,617	528 Added 5.43%	10,248 $2.08 Million
Q4 2019 Jan 22, 2020	BUY	$189.21 - $243.2 $634,988 - $816,179	3,356 Added 52.73%	9,720 $2.34 Million
Q3 2019 Nov 13, 2019	BUY	$174.11 - $208.62 $76,434 - $91,584	439 Added 7.41%	6,364 $1.23 Million
Q2 2019 Aug 23, 2019	BUY	$166.7 - $195.41 $987,697 - $1.16 Million	5,925 New	5,925 $1.1 Million
Q2 2019 Aug 15, 2019	SELL	$166.7 - $195.41 $943,521 - $1.11 Million	-5,660 Closed	0 $0
Q1 2019 Apr 25, 2019	SELL	$180.87 - $203.88 $37,801 - $42,610	-209 Reduced 3.56%	5,660 $1.08 Million
Q4 2018 Feb 15, 2019	SELL	$178.4 - $208.25 $75,463 - $88,089	-423 Reduced 6.72%	5,869 $1.14 Million
Q3 2018 Nov 13, 2018	BUY	$185.29 - $208.89 $124,514 - $140,374	672 Added 11.96%	6,292 $1.3 Million
Q2 2018 Jul 25, 2018	BUY	$166.05 - $186.51 $158,411 - $177,930	954 Added 20.45%	5,620 $1.04 Million
Q1 2018 May 10, 2018	SELL	$169.43 - $198.0 $5,591 - $6,534	-33 Reduced 0.7%	4,666 $795,000
Q4 2017 Feb 08, 2018	BUY	$168.79 - $188.59 $5,907 - $6,600	35 Added 0.75%	4,699 $847,000
Q3 2017 Nov 02, 2017	SELL	$167.29 - $191.0 $11,877 - $13,561	-71 Reduced 1.5%	4,664 $865,000
Q2 2017 Nov 01, 2017	BUY	N/A	66 Added 1.41%	4,735 $815,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,346 Added 100.99%	4,669 $804,000
Q1 2017 Nov 01, 2017	SELL	N/A	-84 Reduced 3.49%	2,323 $377,000
Q4 2016 Nov 01, 2017	BUY	N/A	2,407	2,407 $403,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rfg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rfg Advisory, LLC with notifications on news.

Account